BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced ...
Serve You Rx teams with Pear to lead access to prescription digital therapeutics (PDTs) with proven outcomes in treating substance use disorder (SUD) and opioid use disorder (OUD) and to support ...
BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...
Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years compared with normal treatment alone. Treatment as usual was ...
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer ...
Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...
BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced ...
SelectHealth has signed on with Pear Therapeutics to cover its reSET-O digital tool for opioid use disorder. The non-profit insurer, a subsidiary of Intermountain Healthcare, will make the ...
Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback